Kennedy Jr, President Donald Trump's pick to run the top U.S. health agency, argued on Thursday that his controversial views on vaccines were misrepresented in a charged Senate Health committee hearing,
Robert F. Kennedy Jr, President Donald Trump's pick to run the top U.S. health agency, came under pointed questioning from the top Republican on the Senate Health committee on Thursday who said he had reservations about the nominee's "misleading arguments" on vaccines.
If confirmed by the Senate to be the nation’s health secretary, Robert F. Kennedy Jr. would have vast powers over immunization policies for children and adults.
Vaccination bills are popping up in more than 15 states as lawmakers aim to potentially resurrect or create new religious exemptions from immunization mandates, establish state-level vaccine injury databases or dictate what providers must tell patients about the shots.
Healthline also offers the following tips for preventing TB infections: Wash your hands often and cover your mouth when coughing or sneezing. Eat a nutritious diet and exercise regularly to keep your immune system strong.
If confirmed as health secretary, Robert F. Kennedy Jr. would oversee the Food and Drug Administration and other agencies that issue key decisions for drug companies.
Robert F. Kennedy Jr. transferred ownership of the trademark application in December and its abbreviation — MAHA — to an LLC managed by Del Bigtree.
Kennedy, a Democrat who ended up supporting Trump in the 2024 presidential campaign, faced a confirmation grilling Wednesday over his controversial views -- on everything from vaccines to abortion -- that have both Republicans and Democrats raising concerns.
The ‘Curb Your Enthusiasm’ star supported her husband at his grueling confirmation hearing Wednesday, just as she supported him during their 2019 trip to Samoa, where his meetings with
Robert F. Kennedy Jr.'s long record of doubting the safety of childhood vaccinations persisted as a flash point for him Thursday in a confirmation hearing.
A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of Pittsburgh and NIH Vaccine Research Center researchers report in Science.